TapewireFind a company

person · Reporting owner

Grossman Jerrold B

Disclosed activity across 1 company

Tapewire entity
43461
SEC CIK
0001542519

Export transaction history ↓

Reported relationships

Latest disclosed role at each company.

CompanyLast reported asReport datePublished
ADMA BIOLOGICS, INC.ADMA · Entity 4477DirectorMay 27, 2026May 28, 2026

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

ADMA BIOLOGICS, INC.

Report date May 27, 2026 · Filed May 28, 2026

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Common StockSEC Table I · non-derivativeDirect520,284 Reported balance After 2026-05-27 transaction · row 1 Account or security details depend on footnotes; rows are not merged.
1 source row

Row 1 · 2026-05-27 · Purchase · Acquired 6,400 · Balance 520,284

F1: Represents an open market purchase in a single transaction.

F2: Includes, as of the transaction date, (i) 10,690 RSUs granted on February 9, 2026, half of which will vest on August 9, 2026, and the other half of which will vest on February 9, 2027, subject to the Reporting Person's continued service as of each such vesting date; and (ii) 509,594 shares of common stock owned by the Reporting Person.

Common StockSEC Table I · non-derivativeIndirectSee footnote22,857 Reported balance Holding disclosure · report date 2026-05-27 · row 2 Holding and transaction disclosures are not merged.
1 source row

Row 2 · Balance 22,857

F3: These shares are owned by Brookwood LLC ("Brookwood"). The Reporting Person is the managing member of Brookwood.

Common StockSEC Table I · non-derivativeIndirectSee footnote31,381 Reported balance Holding disclosure · report date 2026-05-27 · row 3 Holding and transaction disclosures are not merged.
1 source row

Row 3 · Balance 31,381

F4: These shares are owned by the Jerrold Grossman 2019 Irrevocable Trust, of which Dr. Grossman serves as investment trustee.

Common StockSEC Table I · non-derivativeIndirectSee footnote38,294 Reported balance Holding disclosure · report date 2026-05-27 · row 4 Holding and transaction disclosures are not merged.
1 source row

Row 4 · Balance 38,294

F5: These shares are owned by Genesis Foundation Inc. ("Genesis"). The Reporting Person is the President of Genesis.

Common StockSEC Table I · non-derivativeIndirectSee footnote175 Reported balance Holding disclosure · report date 2026-05-27 · row 5 Holding and transaction disclosures are not merged.
1 source row

Row 5 · Balance 175

F6: These shares are owned by the Reporting Person's wife.

Filing footnotes · ownership attribution and instrument terms

F1: Represents an open market purchase in a single transaction.

F2: Includes, as of the transaction date, (i) 10,690 RSUs granted on February 9, 2026, half of which will vest on August 9, 2026, and the other half of which will vest on February 9, 2027, subject to the Reporting Person's continued service as of each such vesting date; and (ii) 509,594 shares of common stock owned by the Reporting Person.

F3: These shares are owned by Brookwood LLC ("Brookwood"). The Reporting Person is the managing member of Brookwood.

F4: These shares are owned by the Jerrold Grossman 2019 Irrevocable Trust, of which Dr. Grossman serves as investment trustee.

F5: These shares are owned by Genesis Foundation Inc. ("Genesis"). The Reporting Person is the President of Genesis.

F6: These shares are owned by the Reporting Person's wife.

Transaction history

JSON API
Reset

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction dateCompanyActivity / securityShares / unitsReported priceReported valueDetails
May 27, 2026 Filed May 28, 2026 20:05 UTC ADMA BIOLOGICS, INC. ADMA · Entity 4477 PurchaseCommon Stock 6,400 $7.91 $50,624.00
Disclosure

SEC source: 0001140361-26-023127 · form4.xml · nonDerivative · entry 1

Grossman Jerrold B · CIK 0001542519 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 520,284

F1 · balance_after: Represents an open market purchase in a single transaction.

F2 · balance_after: Includes, as of the transaction date, (i) 10,690 RSUs granted on February 9, 2026, half of which will vest on August 9, 2026, and the other half of which will vest on February 9, 2027, subject to the Reporting Person's continued service as of each such vesting date; and (ii) 509,594 shares of common stock owned by the Reporting Person.

Read SEC document
May 12, 2026 Filed May 14, 2026 11:00 UTC ADMA BIOLOGICS, INC. ADMA · Entity 4477 PurchaseCommon Stock 12,500 $8.01 $100,125.00
Disclosure

SEC source: 0001140361-26-021150 · form4.xml · nonDerivative · entry 1

Grossman Jerrold B · CIK 0001542519 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 513,884

F1 · balance_after: Represents an open market purchase in a single transaction.

F2 · balance_after: Includes, as of the transaction date, (i) 10,690 RSUs granted on February 9, 2026, half of which will vest on August 9, 2026, and the other half of which will vest on February 9, 2027, subject to the Reporting Person's continued service as of each such vesting date; and (ii) 503,194 shares of common stock owned by the Reporting Person.

Read SEC document
May 11, 2026 Filed May 12, 2026 21:22 UTC ADMA BIOLOGICS, INC. ADMA · Entity 4477 PurchaseCommon Stock 12,500 $8.01 $100,125.00
Disclosure

SEC source: 0001140361-26-020855 · form4.xml · nonDerivative · entry 1

Grossman Jerrold B · CIK 0001542519 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 501,384

F1 · balance_after: Represents an open market purchase in a single transaction.

F2 · balance_after: Includes, as of the transaction date, (i) 10,690 RSUs granted on February 9, 2026, which will fully vest on February 9, 2027, subject to the Reporting Person's continued service as of such vesting date; and (ii) 490,694 shares of common stock owned by the reporting person.

Read SEC document
February 09, 2026 Filed Feb 12, 2026 02:00 UTC ADMA BIOLOGICS, INC. ADMA · Entity 4477 GrantStock Option (Right to Buy) · Derivative 17,730 $0.00 Strike: $16.37 $0.00
Disclosure

SEC source: 0001140361-26-004892 · form4.xml · derivative · entry 6

Grossman Jerrold B · CIK 0001542519 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 17,730

Underlying: Common Stock · 17,730 shares

Expires 2036-02-09

F7 · derivative.exercise_date: These options vest in twelve equal monthly installments, becoming fully vested on the one-year anniversary of the date of grant.

Read SEC document
February 09, 2026 Filed Feb 12, 2026 02:00 UTC ADMA BIOLOGICS, INC. ADMA · Entity 4477 GrantCommon Stock 10,690 $0.00 $0.00
Disclosure

SEC source: 0001140361-26-004892 · form4.xml · nonDerivative · entry 1

Grossman Jerrold B · CIK 0001542519 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 488,884

F1 · shares: These shares represent restricted stock units ("RSUs") that will vest in two equal installments, on the six- and 12-month anniversaries of the grant date, becoming fully vested on the one-year anniversary of the grant date, subject to the Reporting Person's continued service as of the applicable vesting date.

F2 · balance_after: Includes, as of the transaction date, (i) 10,690 RSUs granted on February 9, 2026, which will fully vest on February 9, 2027, subject to the Reporting Person's continued service as of such vesting date; (ii) 5,445 RSUs out of 10,889 RSUs granted on February 19, 2025, which will vest fully on February 19, 2026, subject to the Reporting Person's continued service as of such vesting date; and (iii) 472,749 shares of common stock owned by the reporting person.

Read SEC document
June 09, 2025 Filed Jun 11, 2025 01:00 UTC ADMA BIOLOGICS, INC. ADMA · Entity 4477 Exercise / conversionStock Option (right to buy) · Derivative 10,000 $0.00 Strike: $5.00 $0.00
Disclosure

SEC source: 0001140361-25-022113 · form4.xml · derivative · entry 7

Grossman Jerrold B · CIK 0001542519 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 10,000 shares

Expires 2027-02-14

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F7 · derivative.exercise_date: These options were granted on February 14, 2017 and vested in twenty-four equal monthly installments, becoming fully vested on February 14, 2019.

Read SEC document
June 09, 2025 Filed Jun 11, 2025 01:00 UTC ADMA BIOLOGICS, INC. ADMA · Entity 4477 SaleCommon Stock 10,000 $21.31 $213,100.00
Disclosure

SEC source: 0001140361-25-022113 · form4.xml · nonDerivative · entry 2

Grossman Jerrold B · CIK 0001542519 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 478,194

F1 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $21.29 to $21.35. The reporting person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer, full information regarding the number of shares sold at each separate price.

F2 · balance_after: Includes, as of the transaction date, (i) 10,889 restricted stock units granted on February 19, 2025, which will vest in full on February 19, 2026, subject to the Reporting Person's continued service as of the applicable vesting date; and (ii) 467,305 shares of common stock owned by the reporting person.

Read SEC document
June 09, 2025 Filed Jun 11, 2025 01:00 UTC ADMA BIOLOGICS, INC. ADMA · Entity 4477 Exercise / conversionCommon Stock 10,000 $5.00 $50,000.00
Disclosure

SEC source: 0001140361-25-022113 · form4.xml · nonDerivative · entry 1

Grossman Jerrold B · CIK 0001542519 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 488,194

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
February 19, 2025 Filed Feb 22, 2025 02:05 UTC ADMA BIOLOGICS, INC. ADMA · Entity 4477 GrantStock Option (Right to Buy) · Derivative 16,279 $0.00 Strike: $16.07 $0.00
Disclosure

SEC source: 0001140361-25-005538 · form4.xml · derivative · entry 6

Grossman Jerrold B · CIK 0001542519 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 16,279

Underlying: Common Stock · 16,279 shares

Expires 2035-02-19

F7 · derivative.exercise_date: The options vest in 12 equal monthly installments, becoming fully vested on the one-year anniversary of the date of grant.

Read SEC document
February 19, 2025 Filed Feb 22, 2025 02:05 UTC ADMA BIOLOGICS, INC. ADMA · Entity 4477 GrantCommon Stock 10,889 $0.00 $0.00
Disclosure

SEC source: 0001140361-25-005538 · form4.xml · nonDerivative · entry 1

Grossman Jerrold B · CIK 0001542519 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 478,194

F1 · shares: These shares represent restricted stock units ("RSUs") that will vest in two equal installments, on the six- and 12-month anniversaries of the grant date, becoming fully vested on the one-year anniversary of the grant date, subject to the Reporting Person's continued service as of the applicable vesting date.

F2 · balance_after: Includes, as of the transaction date, (i) 10,889 RSUs granted on February 19, 2025 and reported on this Form 4, subject to vesting as set forth in footnote (1); (ii) 12,020 restricted stock units granted on February 26, 2024, which will vest in full on February 26, 2025, subject to the Reporting Person's continued service as of the applicable vesting date; and (iii) 455,285 shares of common stock owned by the Reporting Person.

Read SEC document
August 29, 2024 Filed Aug 31, 2024 01:02 UTC ADMA BIOLOGICS, INC. ADMA · Entity 4477 Exercise / conversionCommon Stock · Derivative 9,000 $10.80 Strike: $10.80 $97,200.00
Disclosure

SEC source: 0001140361-24-039821 · form4.xml · derivative · entry 11

Grossman Jerrold B · CIK 0001542519 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 9,000 shares

Expires 2025-01-30

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F10 · shares: The Reporting Person is exercising these options due, in part, to their near-term expiration date.

F9 · derivative.exercise_date: These options were granted on January 30, 2015 and vested in twenty-four equal monthly installments, becoming fully vested on January 30, 2017.

Read SEC document
August 29, 2024 Filed Aug 31, 2024 01:02 UTC ADMA BIOLOGICS, INC. ADMA · Entity 4477 Exercise / conversionCommon Stock · Derivative 9,000 $5.96 Strike: $5.96 $53,640.00
Disclosure

SEC source: 0001140361-24-039821 · form4.xml · derivative · entry 10

Grossman Jerrold B · CIK 0001542519 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 9,000 shares

Expires 2026-01-28

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F10 · shares: The Reporting Person is exercising these options due, in part, to their near-term expiration date.

F8 · derivative.exercise_date: These options were granted on January 28, 2016 and vested in twenty-four equal monthly installments, becoming fully vested on January 28, 2018.

Read SEC document
August 29, 2024 Filed Aug 31, 2024 01:02 UTC ADMA BIOLOGICS, INC. ADMA · Entity 4477 Exercise / conversionCommon Stock · Derivative 118,861 $3.66 Strike: $3.66 $435,031.26
Disclosure

SEC source: 0001140361-24-039821 · form4.xml · derivative · entry 9

Grossman Jerrold B · CIK 0001542519 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 118,861 shares

Expires 2027-06-06

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F7 · derivative.exercise_date: These options were granted on June 6, 2017 and vested in twenty-four equal monthly installments, becoming fully vested on June 6, 2019.

Read SEC document
August 29, 2024 Filed Aug 31, 2024 01:02 UTC ADMA BIOLOGICS, INC. ADMA · Entity 4477 SaleCommon Stock 136,861 $17.27 $2,363,931.62
Disclosure

SEC source: 0001140361-24-039821 · form4.xml · nonDerivative · entry 4

Grossman Jerrold B · CIK 0001542519 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 467,305

F1 · price: The price reported in Column 4 is the weighted average price. These shares were sold in multiple transactions at prices ranging from $17.17 to $17.595. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer, full information regarding the number of shares sold at each separate price.

F2 · balance_after: Includes, as of the transaction date, (i) 12,020 restricted stock units granted on February 26, 2024, which will vest in full on February 26, 2025, subject to the Reporting Person's continued service as of the applicable vesting date; and (ii) 455,285 shares of common stock owned by the reporting person.

Read SEC document
August 29, 2024 Filed Aug 31, 2024 01:02 UTC ADMA BIOLOGICS, INC. ADMA · Entity 4477 Exercise / conversionCommon Stock 9,000 $10.80 $97,200.00
Disclosure

SEC source: 0001140361-24-039821 · form4.xml · nonDerivative · entry 3

Grossman Jerrold B · CIK 0001542519 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 604,166

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
August 29, 2024 Filed Aug 31, 2024 01:02 UTC ADMA BIOLOGICS, INC. ADMA · Entity 4477 Exercise / conversionCommon Stock 9,000 $5.96 $53,640.00
Disclosure

SEC source: 0001140361-24-039821 · form4.xml · nonDerivative · entry 2

Grossman Jerrold B · CIK 0001542519 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 595,166

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
August 29, 2024 Filed Aug 31, 2024 01:02 UTC ADMA BIOLOGICS, INC. ADMA · Entity 4477 Exercise / conversionCommon Stock 118,861 $3.66 $435,031.26
Disclosure

SEC source: 0001140361-24-039821 · form4.xml · nonDerivative · entry 1

Grossman Jerrold B · CIK 0001542519 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 586,166

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
February 26, 2024 Filed Feb 29, 2024 02:00 UTC ADMA BIOLOGICS, INC. ADMA · Entity 4477 GrantStock Option (right to buy) · Derivative 37,541 $0.00 Strike: $5.40 $0.00
Disclosure

SEC source: 0001140361-24-010241 · form4.xml · derivative · entry 6

Grossman Jerrold B · CIK 0001542519 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 37,541

Underlying: Common Stock · 37,541 shares

Expires 2034-02-26

F7 · derivative.exercise_date: The options vest in 12 equal monthly installments, becoming fully vested on the one-year anniversary of the date of grant.

Read SEC document
February 26, 2024 Filed Feb 29, 2024 02:00 UTC ADMA BIOLOGICS, INC. ADMA · Entity 4477 GrantCommon Stock 24,040 $0.00 $0.00
Disclosure

SEC source: 0001140361-24-010241 · form4.xml · nonDerivative · entry 1

Grossman Jerrold B · CIK 0001542519 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 467,305

F1 · shares: These shares represent restricted stock units ("RSUs") that will vest in two equal installments, on the six- and 12-month anniversaries of the grant date, becoming fully vested on the one-year anniversary of the grant date, subject to the reporting person's continued service as of the applicable vesting date.

F2 · balance_after: Includes, as of the transaction date, (i) 24,040 RSUs granted on February 26, 2024 and reported on this Form 4, subject to vesting as set forth in footnote (1); (ii) 25,815 RSUs granted on March 6, 2023, which will vest in full on March 6, 2024; and (iii) 417,450 shares of common stock owned by the reporting person.

Read SEC document
August 30, 2023 Filed Aug 30, 2023 20:58 UTC ADMA BIOLOGICS, INC. ADMA · Entity 4477 PurchaseCommon Stock 130,000 $3.71 $482,144.00
Disclosure

SEC source: 0001140361-23-041848 · form4.xml · nonDerivative · entry 1

Grossman Jerrold B · CIK 0001542519 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 443,265

F1 · price: Reflects the weighted average price of purchases on August 30, 2023. The shares were purchased in multiple transactions ranging from $3.70 to $3.71, inclusive.

F2 · balance_after: Includes, as of the transaction date, (i) 25,815 RSUs granted on March 6, 2023 that will vest in two equal installments, on the six- and 12-month anniversaries of the grant date, becoming fully vested on the one-year anniversary of the grant date, subject to the reporting person's continued service as of the applicable vesting date; and (ii) 417,450 shares of common stock owned by the reporting person.

Read SEC document
March 06, 2023 Filed Mar 9, 2023 02:30 UTC ADMA BIOLOGICS, INC. ADMA · Entity 4477 GrantEmployee Stock Option (right to buy) · Derivative 51,630 $0.00 Strike: $3.35 $0.00
Disclosure

SEC source: 0001140361-23-010772 · form4.xml · derivative · entry 6

Grossman Jerrold B · CIK 0001542519 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 51,630

Underlying: Common Stock · 51,630 shares

Expires 2033-03-06

F7 · derivative.exercise_date: The options vest in 12 equal monthly installments, becoming fully vested on the one-year anniversary of the date of grant.

Read SEC document
March 06, 2023 Filed Mar 9, 2023 02:30 UTC ADMA BIOLOGICS, INC. ADMA · Entity 4477 GrantCommon Stock 25,815 $0.00 $0.00
Disclosure

SEC source: 0001140361-23-010772 · form4.xml · nonDerivative · entry 1

Grossman Jerrold B · CIK 0001542519 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 313,265

F1 · shares: These shares represent restricted stock units ("RSUs") that will vest in two equal installments, on the six- and 12-month anniversaries of the grant date, becoming fully vested on the one-year anniversary of the grant date, subject to the reporting person's continued service as of the applicable vesting date.

F2 · balance_after: Includes, as of the transaction date, (i) 25,815 RSUs granted on March 6, 2023 and reported on this Form 4, subject to vesting as set forth in footnote (1); (ii) 13,293 RSUs granted on March 7, 2022, which will vest in full on March 7, 2023; and (iii) 274,157 shares of common stock owned by the reporting person.

Read SEC document
March 07, 2022 Filed Mar 9, 2022 22:58 UTC ADMA BIOLOGICS, INC. ADMA · Entity 4477 GrantEmployee Stock Option (right to buy) · Derivative 53,172 $0.00 Strike: $1.67 $0.00
Disclosure

SEC source: 0001140361-22-008670 · form4.xml · derivative · entry 6

Grossman Jerrold B · CIK 0001542519 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 53,172

Underlying: Common Stock · 53,172 shares

Expires 2032-03-07

F7 · derivative.exercise_date: The options vest in 12 equal monthly installments, becoming fully vested on the one-year anniversary of the date of grant.

Read SEC document
March 07, 2022 Filed Mar 9, 2022 22:58 UTC ADMA BIOLOGICS, INC. ADMA · Entity 4477 GrantCommon Stock 26,586 $0.00 $0.00
Disclosure

SEC source: 0001140361-22-008670 · form4.xml · nonDerivative · entry 1

Grossman Jerrold B · CIK 0001542519 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 287,450

F1 · shares: These shares represent restricted stock units ("RSUs") that will vest in two equal installments, on the six- and 12-month anniversaries of the grant date, becoming fully vested on the one-year anniversary of the grant date, subject to the reporting person's continued service as of the applicable vesting date.

F2 · balance_after: Includes (i) 26,586 RSUs granted on March 7, 2022 and reported on this Form 4, subject to vesting as set forth in footnote (1); and (ii) 260,864 shares of common stock owned by the reporting person.

Read SEC document
October 25, 2021 Filed Oct 26, 2021 11:00 UTC ADMA BIOLOGICS, INC. ADMA · Entity 4477 PurchaseCommon Stock 100,000 $1.00 $100,000.00
Disclosure

SEC source: 0001140361-21-035381 · form4.xml · nonDerivative · entry 1

Grossman Jerrold B · CIK 0001542519 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 260,864

F1 · shares: Represents a purchase from the underwriters in the October 2021 public offering of the issuer.

Read SEC document
February 25, 2021 Filed Mar 2, 2021 02:03 UTC ADMA BIOLOGICS, INC. ADMA · Entity 4477 GrantStock Option (right to buy) · Derivative 55,000 $0.00 Strike: $2.35 $0.00
Disclosure

SEC source: 0001193805-21-000295 · e620330_4-jgrossman.xml · derivative · entry 1

Grossman Jerrold B · CIK 0001542519 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 55,000

Underlying: Common Stock · 55,000 shares

Expires 2031-02-25

F1 · derivative.exercise_date: The options vest in twelve equal monthly installments, becoming fully vested on February 25, 2022.

Read SEC document
September 10, 2020 Filed Sep 11, 2020 12:00 UTC ADMA BIOLOGICS, INC. ADMA · Entity 4477 PurchaseCommon Stock 5,000 $2.22 $11,100.00
Disclosure

SEC source: 0001193805-20-001135 · e619926_4-jgrossman.xml · nonDerivative · entry 1

Grossman Jerrold B · CIK 0001542519 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 160,864

F1 · balance_after: Includes 3,750 RSUs granted on February 28, 2020 which remain unvested as of the date hereof and will become fully vested on February 28, 2021, subject to the reporting person's continued service as of the applicable vesting date, and will be settled into common stock upon vesting.

Read SEC document
August 21, 2020 Filed Aug 25, 2020 12:00 UTC ADMA BIOLOGICS, INC. ADMA · Entity 4477 PurchaseCommon Stock 300 $2.62 $786.00
Disclosure

SEC source: 0001193805-20-001069 · e619888_4-jgrossman.xml · nonDerivative · entry 2

Grossman Jerrold B · CIK 0001542519 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 155,864

F1 · balance_after: Includes 7,500 RSUs granted on February 28, 2020, which will vest in two equal installments, on the six- and 12-month anniversaries of the grant, becoming fully vested on the one-year anniversary of the grant, subject to the reporting person's continued service as of the applicable vesting date, and will be settled into common stock upon vesting.

Read SEC document
August 21, 2020 Filed Aug 25, 2020 12:00 UTC ADMA BIOLOGICS, INC. ADMA · Entity 4477 PurchaseCommon Stock 5,000 $2.56 $12,800.00
Disclosure

SEC source: 0001193805-20-001069 · e619888_4-jgrossman.xml · nonDerivative · entry 1

Grossman Jerrold B · CIK 0001542519 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 155,564

F1 · balance_after: Includes 7,500 RSUs granted on February 28, 2020, which will vest in two equal installments, on the six- and 12-month anniversaries of the grant, becoming fully vested on the one-year anniversary of the grant, subject to the reporting person's continued service as of the applicable vesting date, and will be settled into common stock upon vesting.

Read SEC document
August 12, 2020 Filed Aug 13, 2020 12:01 UTC ADMA BIOLOGICS, INC. ADMA · Entity 4477 PurchaseCommon Stock 5,000 $2.90 $14,475.00
Disclosure

SEC source: 0001193805-20-001023 · e619872_4-jgrossman.xml · nonDerivative · entry 3

Grossman Jerrold B · CIK 0001542519 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 150,564

F1 · balance_after: Includes 7,500 RSUs granted on February 28, 2020, which will vest in two equal installments, on the six- and 12-month anniversaries of the grant, becoming fully vested on the one-year anniversary of the grant, subject to the reporting person's continued service as of the applicable vesting date, and will be settled into common stock upon vesting.

Read SEC document
August 12, 2020 Filed Aug 13, 2020 12:01 UTC ADMA BIOLOGICS, INC. ADMA · Entity 4477 PurchaseCommon Stock 5,000 $2.89 $14,450.00
Disclosure

SEC source: 0001193805-20-001023 · e619872_4-jgrossman.xml · nonDerivative · entry 2

Grossman Jerrold B · CIK 0001542519 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 145,564

F1 · balance_after: Includes 7,500 RSUs granted on February 28, 2020, which will vest in two equal installments, on the six- and 12-month anniversaries of the grant, becoming fully vested on the one-year anniversary of the grant, subject to the reporting person's continued service as of the applicable vesting date, and will be settled into common stock upon vesting.

Read SEC document
August 12, 2020 Filed Aug 13, 2020 12:01 UTC ADMA BIOLOGICS, INC. ADMA · Entity 4477 PurchaseCommon Stock 200 $2.87 $574.00
Disclosure

SEC source: 0001193805-20-001023 · e619872_4-jgrossman.xml · nonDerivative · entry 1

Grossman Jerrold B · CIK 0001542519 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 140,564

F1 · balance_after: Includes 7,500 RSUs granted on February 28, 2020, which will vest in two equal installments, on the six- and 12-month anniversaries of the grant, becoming fully vested on the one-year anniversary of the grant, subject to the reporting person's continued service as of the applicable vesting date, and will be settled into common stock upon vesting.

Read SEC document
February 28, 2020 Filed Mar 4, 2020 00:09 UTC ADMA BIOLOGICS, INC. ADMA · Entity 4477 GrantEmployee Stock Option (right to buy) · Derivative 15,000 $0.00 Strike: $2.92 $0.00
Disclosure

SEC source: 0001193805-20-000288 · e619422_4-jgrossman.xml · derivative · entry 6

Grossman Jerrold B · CIK 0001542519 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 15,000

Underlying: Common Stock · 15,000 shares

Expires 2030-02-28

F7 · derivative.exercise_date: The option vests in 12 equal monthly installments, becoming fully vested on the one-year anniversary of the date of grant.

Read SEC document
February 28, 2020 Filed Mar 4, 2020 00:09 UTC ADMA BIOLOGICS, INC. ADMA · Entity 4477 GrantCommon Stock 7,500 $0.00 $0.00
Disclosure

SEC source: 0001193805-20-000288 · e619422_4-jgrossman.xml · nonDerivative · entry 1

Grossman Jerrold B · CIK 0001542519 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 140,364

F1 · shares: These shares represent restricted stock units ("RSUs"), which will vest in 12 equal monthly installments, becoming fully vested on the one-year anniversary of the grant, subject to the reporting person's continued service as of the applicable vesting date, and will be settled into common stock upon vesting.

F2 · balance_after: Includes (i) 7,500 RSUs granted on February 28, 2020 and reported on this Form 4, subject to vesting as set forth in footnote (1) and will be settled into common stock upon vesting; and (ii) 132,864 shares of common stock owned by the reporting person.

Read SEC document
February 28, 2020 Filed May 1, 2020 21:12 UTC Amendment ADMA BIOLOGICS, INC. ADMA · Entity 4477 GrantCommon Stock 7,500 $0.00 $0.00
Disclosure

SEC source: 0001193805-20-000552 · e619598_4a-jgrossman.xml · nonDerivative · entry 1

Grossman Jerrold B · CIK 0001542519 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 140,364

F1 · shares: These shares represent restricted stock units ("RSUs"). Subsequent to the filing of the initial Form 4 by the Reporting Person on March 3, 2020, the Board of Directors of the Issuer corrected the vesting schedule of the RSUs. The RSUs will vest in two equal installments, on the six- and 12-month anniversaries of the grant, becoming fully vested on the one-year anniversary of the grant, subject to the reporting person's continued service as of the applicable vesting date, and will be settled into common stock upon vesting.

F2 · balance_after: Includes (i) 7,500 RSUs granted on February 28, 2020 and reported on this Form 4, subject to vesting as set forth in footnote (1) and will be settled into common stock upon vesting; and (ii) 132,864 shares of common stock owned by the reporting person.

Read SEC document
February 11, 2020 Filed Feb 11, 2020 15:15 UTC ADMA BIOLOGICS, INC. ADMA · Entity 4477 PurchaseCommon Stock 22,857 $3.50 $79,999.50
Disclosure

SEC source: 0001193805-20-000131 · e619334_4-jgrossman.xml · nonDerivative · entry 2

Grossman Jerrold B · CIK 0001542519 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 22,857

F1 · shares: Represents a purchase from the underwriters in the Issuer's public offering.

F2 · ownership.nature: These shares are owned by Brookwood LLC ("Brookwood"). The reporting person is the managing member of Brookwood.

Read SEC document
February 11, 2020 Filed Feb 11, 2020 15:15 UTC ADMA BIOLOGICS, INC. ADMA · Entity 4477 PurchaseCommon Stock 22,857 $3.50 $79,999.50
Disclosure

SEC source: 0001193805-20-000131 · e619334_4-jgrossman.xml · nonDerivative · entry 1

Grossman Jerrold B · CIK 0001542519 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 132,864

F1 · shares: Represents a purchase from the underwriters in the Issuer's public offering.

Read SEC document
May 17, 2019 Filed May 21, 2019 11:14 UTC ADMA BIOLOGICS, INC. ADMA · Entity 4477 PurchaseCommon Stock 12,000 $4.00 $48,000.00
Disclosure

SEC source: 0001193805-19-000524 · e618483_4-jgrossman.xml · nonDerivative · entry 1

Grossman Jerrold B · CIK 0001542519 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 110,007

F1 · shares: Represents a purchase from the underwriters in the Issuer's public offering.

Read SEC document
March 13, 2019 Filed Mar 15, 2019 21:01 UTC ADMA BIOLOGICS, INC. ADMA · Entity 4477 GrantStock Option (right to buy) · Derivative 30,000 $0.00 Strike: $3.89 $0.00
Disclosure

SEC source: 0001193805-19-000295 · e618304_4-jgrossman.xml · derivative · entry 1

Grossman Jerrold B · CIK 0001542519 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 30,000

Underlying: Common Stock · 30,000 shares

Expires 2029-03-13

F1 · derivative.exercise_date: The option vests in twelve equal monthly installments, becoming fully vested on the one-year anniversary of the date of grant.

F2 · derivative.expiration_date: The option terminates on the earlier of (i) March 13, 2029 and (ii) the one-year anniversary of the reporting person's ceasing to serve as a director of the Issuer.

Read SEC document
June 22, 2018 Filed Jun 25, 2018 21:00 UTC ADMA BIOLOGICS, INC. ADMA · Entity 4477 GrantStock Option (right to buy) · Derivative 17,500 $0.00 Strike: $4.91 $0.00
Disclosure

SEC source: 0001193805-18-000901 · e618126_4-jgrossman.xml · derivative · entry 1

Grossman Jerrold B · CIK 0001542519 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 17,500

Underlying: Common Stock · 17,500 shares

Expires 2028-06-22

F1 · derivative.exercise_date: The option vests in twenty-four equal monthly installments, becoming fully vested on the two year anniversary of the date of grant.

F2 · derivative.expiration_date: The option terminates on the earlier of (i) June 22, 2028 and (ii) the one year anniversary of the reporting person's ceasing to serve as a director of the Issuer.

Read SEC document
June 08, 2018 Filed Jun 11, 2018 11:10 UTC ADMA BIOLOGICS, INC. ADMA · Entity 4477 PurchaseCommon Stock 31,381 $4.78 $150,001.18
Disclosure

SEC source: 0001193805-18-000821 · e618087_4-jgrossman.xml · nonDerivative · entry 2

Grossman Jerrold B · CIK 0001542519 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 31,381

F1 · shares: Represents a purchase from the underwriters in the Issuer's public offering.

F2 · ownership.nature: These shares are owned by the Jerrold Grossman 2012 Nevada SLAT, of which Dr. Grossman serves as investment trustee.

Read SEC document
June 08, 2018 Filed Jun 11, 2018 11:10 UTC ADMA BIOLOGICS, INC. ADMA · Entity 4477 PurchaseCommon Stock 20,921 $4.78 $100,002.38
Disclosure

SEC source: 0001193805-18-000821 · e618087_4-jgrossman.xml · nonDerivative · entry 1

Grossman Jerrold B · CIK 0001542519 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 98,007

F1 · shares: Represents a purchase from the underwriters in the Issuer's public offering.

Read SEC document
July 13, 2017 Filed Jul 17, 2017 21:13 UTC ADMA BIOLOGICS, INC. ADMA · Entity 4477 Exercise / conversionEmployee Stock Option (right to buy) · Derivative 48,185 $0.00 Strike: $2.68 $0.00
Disclosure

SEC source: 0001193805-17-001299 · e616385_4-jgrossman.xml · derivative · entry 5

Grossman Jerrold B · CIK 0001542519 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 48,185 shares

Expires 2017-07-16

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_date: The shares subject to the option vested in equal monthly installments over the four (4) year period following July 16, 2007.

Read SEC document
July 13, 2017 Filed Jul 17, 2017 21:13 UTC ADMA BIOLOGICS, INC. ADMA · Entity 4477 Tax withholdingCommon Stock 39,132 $3.30 $129,135.60
Disclosure

SEC source: 0001193805-17-001299 · e616385_4-jgrossman.xml · nonDerivative · entry 2

Grossman Jerrold B · CIK 0001542519 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 77,086

Read SEC document
July 13, 2017 Filed Jul 17, 2017 21:13 UTC ADMA BIOLOGICS, INC. ADMA · Entity 4477 Exercise / conversionCommon Stock 48,185 $2.68 $129,135.80
Disclosure

SEC source: 0001193805-17-001299 · e616385_4-jgrossman.xml · nonDerivative · entry 1

Grossman Jerrold B · CIK 0001542519 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 116,218

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
June 06, 2017 Filed Jun 8, 2017 22:02 UTC ADMA BIOLOGICS, INC. ADMA · Entity 4477 GrantStock Option (right to buy) · Derivative 118,861 $0.00 Strike: $3.66 $0.00
Disclosure

SEC source: 0001193805-17-001057 · e616264_4-jgrossman.xml · derivative · entry 1

Grossman Jerrold B · CIK 0001542519 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 118,861

Underlying: Common Stock · 118,861 shares

Expires 2027-06-06

F1 · derivative.exercise_date: The option vests in twenty-four equal monthly installments, becoming fully vested on the two year anniversary of the date of grant.

F2 · derivative.expiration_date: The option terminates on the earlier of (i) June 6, 2027 and (ii) the one year anniversary of the reporting person's ceasing to serve as a director of the Issuer.

Read SEC document
February 14, 2017 Filed Feb 17, 2017 01:12 UTC ADMA BIOLOGICS, INC. ADMA · Entity 4477 GrantStock Option (right to buy) · Derivative 10,000 $0.00 Strike: $5.00 $0.00
Disclosure

SEC source: 0001193805-17-000277 · e615797_4-jgrossman.xml · derivative · entry 1

Grossman Jerrold B · CIK 0001542519 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 10,000

Underlying: Common Stock · 10,000 shares

Expires 2027-02-14

F1 · derivative.exercise_date: The option vests in twenty-four equal monthly installments, becoming fully vested on the two year anniversary of the date of grant.

F2 · derivative.expiration_date: The option terminates on the earlier of (i) February 14, 2027 and (ii) the one year anniversary of the reporting person's ceasing to serve as a director of the Issuer.

Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.